Jeffrey Oram
Alzamend NeuroAbout Jeffrey Oram
Jeffrey Oram (age 57) is an independent director of Alzamend Neuro, serving since 2021. He brings 25+ years of corporate, private, and institutional investment experience, with 13 years focused on institutional real estate capital markets; he holds a B.S. in Biology from Princeton University . Oram’s board tenure began in June 2021; he is currently chair of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees . The Board has affirmatively determined Oram is independent under Nasdaq and SEC rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| CB Richard Ellis | First Vice President | 2003–2009 | Institutional real estate capital markets leadership |
| Marcus & Millichap | Director | 2009–2011 | Institutional real estate capital markets leadership |
| Colliers International | Executive Managing Director | 2011–2016 | Institutional real estate capital markets leadership |
| New Jersey State Investment Council | Executive Member | 2010–2018 | Oversight of NJ state pension investments |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Godby Realtors | Principal | Since 2016 | Private real estate investment/brokerage |
| New Jersey State Investment Council | Executive Member | 2010–2018 | State pension governance oversight |
Board Governance
- Independence: The Board determined Oram is independent; only Ault (Vice Chair), Jackman (CEO), and Nisser (EVP/GC) are non‑independent .
- Committee assignments and chair roles: Oram is Audit Committee member; Compensation Committee member; and Chair of Nominating & Corporate Governance .
- Attendance: In FY ended April 30, 2024 the Board met 13 times; Audit 7; Compensation 3; Nominating & Corporate Governance 0; all incumbent directors attended ≥75% of meetings of the Board/committees on which they served .
- Board leadership: William B. Horne is Board Chair; no Lead Independent Director disclosed .
- Director stock ownership guidelines: None; Board is “satisfied” with current holdings; no hedging policy adopted .
| Committee | Role | Chair? | Notes |
|---|---|---|---|
| Audit | Member | No | Audit has 3 independent members; Gustafson is chair and “financial expert” |
| Compensation | Member | No | Committee comprised of independent directors; did not engage a comp consultant in FY2024 |
| Nominating & Corporate Governance | Member | Yes | Oversees board criteria, nominations, governance guidelines, and board/management evaluations |
Fixed Compensation
| Metric | FY 2024 | Notes |
|---|---|---|
| Annual base retainer (cash) | $25,000 | Company pays independent directors $25,000 base; Board may adjust for above‑anticipated service |
| Fees earned (Oram) | $25,000 | No stock or option awards to directors in FY 2024 |
Performance Compensation
- No director stock awards (RSUs/PSUs) or option awards granted in FY 2024; no performance metrics disclosed for director compensation (e.g., TSR, revenue, EBITDA) .
- The company’s equity plans permit performance awards with metrics (e.g., revenue, EBITDA) generally for employees/executives, but none are disclosed as granted to directors in FY 2024 .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards (Oram) | None disclosed |
| Notable company interlocks (broader board) | Multiple Alzamend directors/executives also hold roles at Hyperscale Data and Ault affiliates (Horne, Nisser, Cragun), indicating related‑party exposure at the company level; no Oram involvement disclosed |
Expertise & Qualifications
- Institutional investment and real estate capital markets background (CBRE, Marcus & Millichap, Colliers; NJ State Investment Council) .
- Governance oversight experience via chair role in Nominating & Corporate Governance (criteria, nominations, governance guidelines, board/management evaluations) .
- Academic credentials: B.S. Biology, Princeton University .
Equity Ownership
| Ownership Item | Amount |
|---|---|
| Common shares owned directly | 666 shares |
| Options exercisable within 60 days | 2,000 shares |
| Total beneficial ownership | 2,666 shares |
| Ownership % of outstanding shares | <1% |
| Vested vs. unvested breakdown | 2,000 options currently exercisable; unvested not disclosed |
| Pledging/Hedging | No pledging disclosed for Oram; company has not adopted any hedging policy |
Section 16(a) compliance: The company believes all filing requirements were met in FY2024, except one Form 5 reporting one Form 4 transaction by a director (not identified) .
Governance Assessment
- Board effectiveness: Oram’s chairmanship of Nominating & Corporate Governance positions him to influence board composition, governance guidelines, and evaluation processes—positive for governance rigor when executed effectively .
- Independence and attendance: Independent status with ≥75% attendance supports baseline governance quality .
- Alignment and incentives: Oram’s FY2024 pay was entirely cash ($25,000) with no annual equity grant; while he holds 666 shares and 2,000 options exercisable within 60 days, ownership remains <1% amid no formal ownership guidelines and no hedging policy—moderate alignment signal with potential for improvement via consistent equity retainer and ownership policy adoption .
- Conflicts/related‑party risk: No Oram‑specific related‑party transactions disclosed. However, the broader company has significant related‑party dealings and overlapping leadership with Ault‑controlled entities (Hyperscale Data; Ault Lending; ALSI), posing governance risk environment; monitoring Oram’s oversight as Nominating & Governance chair is important for investor confidence .
RED FLAGS
- No director stock ownership guidelines; Board explicitly chose not to adopt them .
- No hedging policy adopted, which can weaken alignment .
- Broader company-level related‑party transactions and interlocks with Ault affiliates (not involving Oram directly) elevate conflict‑of‑interest risk that the board must robustly oversee .
- Compensation Committee did not use an independent compensation consultant in FY2024, limiting external benchmarking and governance best‑practice assurance .